ctDNA clearance and outcomes for resectable lung cancer from NeoCOAST-2
The NeoCOAST-2 clinical trial evaluated novel perioperative treatments for resectable non-small cell lung cancer. Results indicate that combining Dato-DXd with standard therapy yields higher pathological complete response and event-free survival rates, with ctDNA clearance serving as a strong predictor of positive outcomes.
Why it matters
This research provides a potential new standard of care for lung cancer patients, utilizing biomarker-driven risk stratification to improve long-term survival.
We’re sharing this article early to provide faster access to peer-reviewed, accepted research. It is citable and carries a permanent DOI. This version is subject to further edits and will be replaced automatically by the final Version of Record. All legal disclaimers apply.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in